In this study, conducted with a limited number of DCM patients, we found thatelevated baseline NT-proBNP (>7390 pg/mL), elevated UA (>542μmol/L), and LVEF reduction (≥3%) during the 2-yearpharmacological treatment period before HTx are significantly linked to anincreased risk of adverse events in young adult DCM patients post-HTx.Confirmation of these findings and the exploration of whether more intensivemonitoring strategies can enhance outcomes for these high-risk patients post-HTxnecessitate further investigation in larger patient cohorts. Here, NPPB is linked to familial dilated cardiomyopathy.